The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

This new class of diabetes drugs may just be too dangerous to take

Four years ago the largest investment bank in the world fired off an urgent alert to all of its investors.

Goldman Sachs warned that a new class of diabetes meds called SGLT2 inhibitors – drugs that were supposed to be the next billion-dollar blockbusters for companies like Bristol-Myers Squibb and Eli Lilly – would probably never see the light of day.

Clinical trials had linked SGLT2 inhibitors like Farxiga to horrible side effects such as breast and bladder cancers and kidney and liver damage. Plus the drugs didn’t work very well.

Stockbrokers and their clients knew all about the terrible risks of SGLT2 inhibitors – but diabetics didn’t.

Since that time, Big Pharma has steamrolled the FDA and gotten six new SGLT2 inhibitors onto the market – one may even be sitting in your medicine cabinet or purse right now. And they’re just as lethal now as they were four years ago.

In fact, the FDA is now admitting that the same drugs it approved may be triggering a serious blood disorder that can lead to a coma – or even death.

New and (NOT) improved

The FDA has sent a warning to doctors and patients that SGLT2 inhibitors like Farxiga, Invokana and Jardiance can cause a life-threatening condition called ketoacidosis.

Ketoacidosis occurs when your body can’t use glucose properly and starts to burn fat for energy instead. If that goes on for too long, the acid levels in your blood skyrocket and you could end up in a diabetic coma or even dead.

It’s the kind of disorder you usually see among patients whose diabetes is poorly controlled – not among people who are forking over their paychecks for some hot new drug like SGLT2 inhibitors.

But at the Endocrine Society’s big annual meeting a couple months ago, researchers from the University of Colorado shared the story of a 50-year-old woman who developed a serious and life-threatening case of ketoacidosis after just six doses of Invokana.

And while the dangers of SGLT2 inhibitors may come as news to diabetics and even their doctors, Wall Street and even some of the FDA’s top advisors have known about them for years.

In 2011, an FDA advisory panel raised so many concerns about Farxiga – which was developed by drug giants Bristol-Myers Squibb and AstraZeneca – that Goldman Sachs analyst Jami Rubin said the chances of any SGLT2 inhibitor ever being approved were “likely dead.”

There were concerns about “not only the drug’s safety but also efficacy,” Rubin wrote. And the trials produced disturbing side effects like an unexplained 500 percent increase in breast and bladder cancers.

“There were questions about serious complications that [the drug companies] tried to finesse,” said Erik Gordon, a professor from the University of Michigan.

Drug experts also warned that SGLT2 inhibitors can threaten your kidneys. They all work essentially the same way, by forcing your kidneys to excrete glucose in your urine.

Even if you have moderately reduced kidney function – which is common among diabetics – the drugs may cause serious and permanent damage.

But despite dire warnings from medical researchers around the country and even members of its own advisory panel, the FDA opened the floodgates by approving Invokana in 2013.

There are now six of these dangerous SGLT2 inhibitors being prescribed to unsuspecting diabetics. Aside from Invokana and Farxiga (yes, the same Farxiga that the FDA panel recommended against), the list includes:

  • Jardiance (linked to urinary tract infections and heart problems);
  • Glyxambi (a combination of Jardiance and a hormone-mimicking med called Tradjenta that’s been linked to pancreatic cancer);
  • Xigduo XR (a combo of Farxiga and metformin that’s been linked to dangerously low blood pressure and bladder cancer); and
  • Invokamet (a combination of Invokana and metformin that may cause potentially fatal lactic acidosis).

While each of these drugs comes with its own list of troubling side effects, it’s important to remember that they can all trigger ketoacidosis. Catching ketoacidosis early is critical, and you need to be on the lookout for telltale symptoms like fatigue; nausea; vomiting; abdominal pain; shortness of breath; excessive thirst; and confusion.

If you’ve been prescribed a SGLT2 inhibitor – and especially if you’re experiencing any of these symptoms – it’s urgent that you speak with your doctor as soon as possible. Hopefully you’re being given a warning and a chance that many diabetics were denied for years.

Sources:

“FDA warns on newer class of type 2 diabetes drugs” Bill Berkrot, May 15, 2015, Reuters, reuters.com

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.